- Home
- MGNX vs PCSC Comparison
MGNX vs PCSC Comparison
Compare MGNX & PCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- PCSC
- Stock Information
- Founded
- MGNX 2000
- PCSC 2024
- Country
- MGNX United States
- PCSC United States
- Employees
- MGNX N/A
- PCSC N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- PCSC
- Sector
- MGNX Health Care
- PCSC
- Exchange
- MGNX Nasdaq
- PCSC NYSE
- Market Cap
- MGNX 97.2M
- PCSC 114.2M
- IPO Year
- MGNX 2013
- PCSC 2024
- Fundamental
- Price
- MGNX $1.36
- PCSC $10.54
- Analyst Decision
- MGNX Hold
- PCSC
- Analyst Count
- MGNX 9
- PCSC 0
- Target Price
- MGNX $5.33
- PCSC N/A
- AVG Volume (30 Days)
- MGNX 378.7K
- PCSC 549.0
- Earning Date
- MGNX 05-13-2025
- PCSC 01-01-0001
- Dividend Yield
- MGNX N/A
- PCSC N/A
- EPS Growth
- MGNX N/A
- PCSC N/A
- EPS
- MGNX N/A
- PCSC N/A
- Revenue
- MGNX $154,050,000.00
- PCSC N/A
- Revenue This Year
- MGNX N/A
- PCSC N/A
- Revenue Next Year
- MGNX $45.52
- PCSC N/A
- P/E Ratio
- MGNX N/A
- PCSC $45.93
- Revenue Growth
- MGNX 255.31
- PCSC N/A
- 52 Week Low
- MGNX $0.99
- PCSC $10.02
- 52 Week High
- MGNX $5.77
- PCSC $10.57
- Technical
- Relative Strength Index (RSI)
- MGNX 39.88
- PCSC N/A
- Support Level
- MGNX $1.44
- PCSC N/A
- Resistance Level
- MGNX $1.58
- PCSC N/A
- Average True Range (ATR)
- MGNX 0.11
- PCSC 0.00
- MACD
- MGNX -0.02
- PCSC 0.00
- Stochastic Oscillator
- MGNX 17.65
- PCSC 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About PCSC PERCEPTIVE CAP SOLUTIONS CORP
Perceptive Capital Solutions Corp is a blank check company.